Brief: Sanofi Selects Innate Pharma's NK Cell Engager As Candidate For Development
21/07/2022 06:05
July 21 (Reuters) - Innate Pharma SA IPH.PA :
* SECOND INNATE PHARMA NK CELL ENGAGER SELECTED BY SANOFI AS
DRUG
CANDIDATE FOR DEVELOPMENT
* SELECTION OF IPH6401/SAR'514 TRIGGERS A EUR 3 MLN
MILESTONE
PAYMENT TO INNATE
Further company coverage: IPH.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Innate Pharma SA
See all newsFrance's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member
French and Benelux stocks-Factors to watch